BODY OPTIMIZATION REPORT

Research before hype.

A free, evidence-led briefing on three of the most talked-about frontiers in recovery, metabolism and healthy aging: what researchers actually studied, in whom, and how much weight the result can carry.

Free PDF · 19 pages · Every finding labeled by evidence level · Unsubscribe anytime

3D mockup of the 19-page Body Optimization Report PDF cover with navy and blue geometric accents

REPORT CURRICULUM

Three frontiers, one honest lens

A 19-page briefing that labels the strength of every finding and flags plainly where the science is still early.

METHOD

Reading evidence like an editor

A 5-level ladder from cell studies to large clinical trials, so you can tell a headline from a finding.

FRONTIER 01

The metabolism frontier

What the newest peer-reviewed trials show about metabolism and body composition, including results published in late 2026.

FRONTIER 02

The regeneration frontier

What tissue-repair research shows in people versus in animals, and exactly where the human evidence runs out.

FRONTIER 03

The growth-hormone frontier

What controlled studies found about the body's own growth-hormone signaling, including a trial that missed its goal.

Instant PDF · 19 pages · 21 sources listed

EVIDENCE ARCHITECTURE

A briefing you can actually check

Every study in the report is tagged with its stage of evidence. Early findings are clearly flagged, so you always know how much weight a result can carry.

Level 5Large trials and approvals (Phase 3)Strongest
Level 4Randomized controlled trials (Phase 2)Strong
Level 3Small human studiesEarly signal
Level 2Animal studiesMay not apply to people
Level 1Cell studiesHypothesis only

"Studied" is not "proven", and "approved for one condition" is not "safe for everyone". We flag the level every time.

INSIDE THE BRIEFING

Eight compounds, reviewed the same way

Each one gets the same treatment: what it is, what the research found, what the risks and open questions are, and where it stands with regulators.

  • Retatrutide: Phase 3 results, peer-reviewed in late 2026
  • Tesamorelin: the only compound here holding an FDA approval
  • MOTS-c: a compelling animal story with no human trials
  • BPC-157: where a two-person safety pilot is the whole human record
  • KPV: cells and mice only, and we say so
  • GHK-Cu: strong topical evidence, weak evidence for anything else
  • CJC-1295 (No DAC): human data that is for a different version of the molecule
  • Ipamorelin: a Phase 2 trial that missed its primary endpoint
Floating perspective mockup of interior report pages showing compound profiles and evidence-level tags

OUR STANDARDS

How we review research

Every briefing follows the same three rules.

RULE 01

Primary sources first

We work from published studies, registered clinical trials and official regulatory records, not headlines or social posts. Every source is linked.

RULE 02

Evidence levels labeled

Every finding is tagged, from cell study to large clinical trial. You never have to guess how strong a result is.

RULE 03

Skeptical by default

We report null results, failed trials and safety signals alongside positive findings. If the human data isn't there, we say so.

Clear sources. Honest evidence levels.

Transparency & Clarity

Common questions

Straight answers about the report.

Who is this report for?

Anyone who keeps seeing these compounds discussed online and wants to know what the research actually says. It is written for a general reader, not for specialists.

Is this medical advice?

No. The report is educational. It is not medical advice and does not replace a licensed healthcare professional. It contains no dosing, protocols or administration guidance.

What does it cost?

Nothing. The report is free. You get the PDF by email within a few minutes of signing up.

Why label everything by evidence level?

Because "a study showed" can mean a Phase 3 trial in thousands of people or an experiment in a dish. Those are not the same claim, and the difference is usually what gets lost online.

Will you email me constantly?

No. You will get the report, then a short series of research summaries. One click unsubscribes you at any time.

Where do the compounds come from?

The report is educational and independent. For readers who go on to source research-grade materials, the briefing names a supplier we partner with and discloses that relationship in full.

FINAL RESEARCH ACCESS

Get the free report

The full 19-page briefing, sent straight to your inbox.

  • Arrives in your inbox within minutes
  • Every finding labeled by evidence level
  • 21 sources, each one linked
  • Unsubscribe anytime with one click

Instant PDF delivery

Enter your details below.